MEREO BIOPHARMA GROUP PLC Interest Expense
MEREO BIOPHARMA GROUP PLC (MREO) reported Interest Expense of $16.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement
us-gaap:InterestExpense · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC interest expense for the quarter ending 2026-06-30 was $16.00K, a 33.33% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC interest expense for the quarter ending 2026-03-31 was $20.00K, a 88.89% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC interest expense for the quarter ending 2025-12-31 was $23.00K, a 93.87% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC interest expense for the quarter ending 2025-09-30 was $28.00K, a 92.07% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC interest expense for fiscal 2025 was $255.00K, a 81.39% decline from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC interest expense for fiscal 2024 was $1.37M, a 52.45% decline from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC interest expense for fiscal 2023 was $2.88M, a 30.99% decline from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC interest expense for fiscal 2022 was $4.17M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.00K 10-Q · filed 2026-08-11 | $37.00K 10-Q · filed 2026-08-11 | $59.00K derived: sum of 3 quarters · filed 2026-08-11 | $87.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-12 | $43.00K derived: sum of 2 quarters · filed 2026-05-12 | $71.00K derived: sum of 3 quarters · filed 2026-05-12 | $95.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $51.00K derived: sum of 2 quarters · filed 2026-03-19 | $75.00K derived: sum of 3 quarters · filed 2026-08-11 | $255.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $28.00K 10-Q · filed 2025-11-10 | $52.00K derived: sum of 2 quarters · filed 2026-08-11 | $232.00K 10-Q · filed 2025-11-10 | $607.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $24.00K 10-Q · filed 2026-08-11 | $204.00K 10-Q · filed 2026-08-11 | $579.00K derived: sum of 3 quarters · filed 2026-08-11 | $932.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $180.00K 10-Q · filed 2026-05-12 | $555.00K derived: sum of 2 quarters · filed 2026-05-12 | $908.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.24M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $375.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $728.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.06M derived: sum of 3 quarters · filed 2026-03-19 | $1.37M 10-K · filed 2026-03-19 |
| 2024-09-30 | $353.00K 10-Q · filed 2025-11-10 | $684.00K derived: sum of 2 quarters · filed 2025-11-10 | $995.00K 10-Q · filed 2025-11-10 | $1.35M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $331.00K 10-Q · filed 2025-08-12 | $641.00K 10-Q · filed 2025-08-12 | $994.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.69M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $310.00K 10-Q · filed 2025-05-13 | $663.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.36M derived: sum of 3 quarters · filed 2025-05-13 | $2.39M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $353.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $1.05M derived: sum of 2 quarters · filed 2025-03-26 | $2.08M derived: sum of 3 quarters · filed 2025-03-26 | $2.88M 10-K · filed 2025-03-26 |
| 2023-09-30 | $700.00K 10-Q · filed 2024-11-12 | $1.73M derived: sum of 2 quarters · filed 2024-11-12 | $2.53M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.03M 10-Q · filed 2024-08-13 | $1.83M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $800.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $4.17M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |